NRX Pharmaceuticals (NRXP) Cash from Financing Activities (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Cash from Financing Activities of $3.4 million for Q1 2026, down 54.86% year-over-year from $7.6 million in Q1 2025, and down 25.16% quarter-over-quarter from $4.6 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Cash from Financing Activities (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Cash from Financing Activities for 10 consecutive years, with $3.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 54.86% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $19.1 million (up 30.26% YoY), while the FY2025 annual figure was $23.3 million, up 210.97% from the prior year.
- Cash from Financing Activities eased to $3.4 million in Q1 2026 per NRXP's latest filing, from $4.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $23.0 million in Q1 2022 and bottomed at -$1.5 million in Q3 2023.
- Historically, Cash from Financing Activities has averaged $4.3 million across 5 years, with a median of $2.5 million in 2023.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities jumped 1012100.0% — and 2023, when it slumped 5260.71%.
- NRX Pharmaceuticals' Cash from Financing Activities stood at $10.1 million in 2022, then sank by 111.03% to -$1.1 million in 2023, then soared by 269.8% to $1.9 million in 2024, then soared by 141.42% to $4.6 million in 2025, then retreated by 25.16% to $3.4 million in 2026.
- Business Quant data shows NRXP's Cash from Financing Activities at $3.4 million in Q1 2026, $4.6 million in Q4 2025, and $9.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 29.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.42 Mn |
| Mar 31, 2026 | 3.42 Mn |
| Dec 31, 2025 | 4.58 Mn |
| Dec 31, 2025 | 4.58 Mn |
| Sep 30, 2025 | 9.73 Mn |
| Sep 30, 2025 | 9.73 Mn |
| Jun 30, 2025 | 1.39 Mn |
| Jun 30, 2025 | 1.39 Mn |
| Mar 31, 2025 | 7.59 Mn |
| Mar 31, 2025 | 7.59 Mn |
| Dec 31, 2024 | 1.90 Mn |
| Dec 31, 2024 | 1.90 Mn |
| Sep 30, 2024 | 2.05 Mn |
| Sep 30, 2024 | 2.05 Mn |
| Jun 30, 2024 | 3.14 Mn |
| Jun 30, 2024 | 3.14 Mn |
| Mar 31, 2024 | 395,000.00 |
| Mar 31, 2024 | 395,000.00 |
| Dec 31, 2023 | -1.12 Mn |
| Dec 31, 2023 | -1.12 Mn |